Abstract |
Abiraterone acetate is a novel CYP17A1 inhibitor demonstrated to prolong survival in castration-resistant prostate cancer (CRPC). This review explores key stages in the almost 20-year history of abiraterone acetate׳s development, starting with a program aiming to develop inhibitors of androgen synthesis at the Institute of Cancer Research, London. Clinical development was initially slow owing to insufficient data supporting targeting of androgen synthesis as a therapeutic approach in CRPC and safety concerns of adrenocortical insufficiency from suppression of cortisol. Regulatory authorities approved abiraterone acetate in 2011 after a survival benefit was demonstrated when given in combination with prednisone as compared with prednisone alone in docetaxel-treated men. Licensing approval extended to include chemotherapy-naive patients with CRPC in 2012 following a significant increase in radiographic progression-free survival. Ongoing research focuses on identifying predictive biomarkers and understanding mechanisms of resistance to improve its administration.
|
Authors | Emily Grist, Gerhardt Attard |
Journal | Urologic oncology
(Urol Oncol)
Vol. 33
Issue 6
Pg. 289-94
(Jun 2015)
ISSN: 1873-2496 [Electronic] United States |
PMID | 26025264
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Abiraterone Acetate
|
Topics |
- Abiraterone Acetate
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Disease Progression
- Disease-Free Survival
- Humans
- Male
- Prostatic Neoplasms, Castration-Resistant
(drug therapy, mortality)
- Treatment Outcome
|